Biofrontera Inc. (BFRI): Depreciation & Amortization
$138.0K
Year ended 2025-12-31
$203.0K
Trailing 12 months to 2026-06-30
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $138.0K | -67.2% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $421.0K | n/a | 2026-03-19, From 2024-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Biofrontera Inc. (BFRI) | 2025-12-31 | $138.0K | -67.2% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $1.46M | +18.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $552.9K | +6.2% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $332.1K | +48.6% |
Compare BFRI, XLO, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗